<p>Boothbay Fund Management LLC 在最近向证券交易委员会的披露中表示，在第一季度减少了对 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - 免费报告) 的持股比例，降幅为 4.4%。该公司在此期间出售了 60,412 股后，持有生物技术公司 1,324,221 股股票。Boothbay Fund Management LLC 在最近一个季度末持有的 BioCryst Pharmaceuticals 的股份约占 0.63%，价值 9,932,000 美元。</p>
<p>其他几家对冲基金和机构投资者最近也对该公司的持仓进行了调整。安联资产管理有限公司在第一季度将其在 BioCryst Pharmaceuticals 的股份增加了 9.6%。安联资产管理有限公司目前持有 13,700 股生物技术公司的股票，价值 103,000 美元，此前在此期间又增持了 1,200 股。加拿大皇家银行在第一季度将其在 BioCryst Pharmaceuticals 的持股增加了 2.4%。加拿大皇家银行目前持有 63,463 股生物技术公司的股票，价值 476,000 美元，此前在此期间又增持了 1,458 股。SG Americas Securities LLC 在第一季度将其在 BioCryst Pharmaceuticals 的股份增加了 5.2%。SG Americas Securities LLC 目前持有 43,496 股生物技术公司的股票，价值 326,000 美元，此前在上个季度又增持了 2,146 股。威灵顿管理集团在第一季度将其在 BioCryst Pharmaceuticals 的持股增加了 2.6%。威灵顿管理集团目前持有 91,348 股生物技术公司的股票，价值 685,000 美元，此前在此期间又增持了 2,291 股。最后，Mariner LLC 在第四季度将其在 BioCryst Pharmaceuticals 的持仓增加了 32.1%。Mariner LLC 目前持有 13,258 股生物技术公司的股票，价值 100,000 美元，此前在上个季度又增持了 3,224 股。目前，85.88% 的股票由机构投资者持有。</p>
<h2>BioCryst Pharmaceuticals 价格表现</h2>
<p>NASDAQ:BCRX 周四开盘价为 8.29 美元。该公司的市值为 17.4 亿美元，市盈率为 -46.05，市盈率增长比率为 1.89，贝塔值为 1.13。该股票的 50 日简单移动平均线为 8.57 美元，200 日简单移动平均线为 8.77 美元。BioCryst Pharmaceuticals, Inc. 的 12 个月最低价为 6.01 美元，最高价为 11.31 美元。</p>
<p>BioCryst Pharmaceuticals (NASDAQ:BCRX - 获取免费报告) 最近于 8 月 4 日星期一发布了季度财报。该生物技术公司报告本季度每股收益为 0.15 美元，超出市场共识预期的 0.03 美元，超出幅度为 0.12 美元。该公司在本季度的收入为 1.6335 亿美元，而市场共识预期为 1.4959 亿美元。BioCryst Pharmaceuticals 本季度的收入同比增长 49.5%。在去年同期，该公司每股收益为 -0.06 美元。分析师平均预计 BioCryst Pharmaceuticals, Inc. 本财年将发布 -0.36 美元的每股收益。</p>
<h2>BioCryst Pharmaceuticals 内部交易</h2>
<p>在其他 BioCryst Pharmaceuticals 的新闻中，董事 Theresa Heggie 于 8 月 13 日星期三出售了 70,000 股该股票。该股票的平均售价为 8.51 美元，总价值为 595,700.00 美元。交易完成后，该董事直接持有公司 65,352 股股票，估值约为 556,145.52 美元。这笔交易代表了他们持有股票的比例减少了 51.72%。该交易已在向证券交易委员会提交的文件中披露，可以通过此链接访问。目前，5.10% 的股票由内部人士持有。</p>
<h2>华尔街分析师观点</h2>
<p>BCRX 是多份研究报告的主题。巴克莱在 5 月 7 日的报告中将 BioCryst Pharmaceuticals 的目标价从 8.00 美元上调至 11.00 美元，并给予该股票 “持平” 评级。Wall Street Zen 在 7 月 26 日的研究报告中将 BioCryst Pharmaceuticals 的评级从 “买入” 上调至 “强力买入”。加拿大皇家银行在 6 月 30 日的报告中重申了 “跑赢大盘” 评级，并对 BioCryst Pharmaceuticals 的股票设定了 13.00 美元的目标价。美国银行在 7 月 1 日的报告中将 BioCryst Pharmaceuticals 的目标价从 13.00 美元上调至 15.00 美元，并给予该股票 “买入” 评级。最后，Wedbush 在 6 月 30 日的研究报告中将 BioCryst Pharmaceuticals 的目标价从 16.00 美元上调至 18.00 美元，并给予该公司 “跑赢大盘” 评级。九位投资分析师对该股票给予了 “买入” 评级，一位分析师给予了 “持有” 评级。根据 MarketBeat.com 的数据，BioCryst Pharmaceuticals 目前的平均评级为 “适度买入”，共识目标价为 16.70 美元。</p>
<p><strong>阅读我们对 BioCryst Pharmaceuticals 的最新分析</strong></p>
<h2>关于 BioCryst Pharmaceuticals</h2>
<p>(免费报告)</p>
<p>BioCryst Pharmaceuticals, Inc. 是一家生物技术公司，开发口服小分子和蛋白质治疗药物以治疗罕见疾病。该公司销售的药物包括用于治疗急性非复杂流感的静脉注射药物 peramivir，商品名为 RAPIVAB、RAPIACTA 和 PERAMIFLU；以及用于治疗遗传性血管性水肿的口服丝氨酸蛋白酶抑制剂 ORLADEYO。</p>
<h2>特色故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 BioCryst Pharmaceuticals</li>
<li>技术股解析：关于科技你需要知道的事</li>
<li>ETF 的回归：三只可能持续表现优异的股票</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>开学购物达到 400 亿美元：现在值得关注的三只零售股票</li>
<li>现在值得购买的三只沃伦·巴菲特股票</li>
<li>Alphabet 股票在躲避严厉的反垄断措施后大幅上涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNSWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 BioCryst 制药吗？</h2>
<p>在考虑 BioCryst 制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 BioCryst 制药并不在名单上。</p>
<p>虽然 BioCryst 制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BioCryst制药

<p>Boothbay Fund Management LLC 在第一季度减少了对 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) 的持股比例，减持了 4.4%，出售了 60,412 股，剩余持有 1,324,221 股，价值约 993 万美元。其他机构投资者也调整了他们的持仓。BioCryst 的股票开盘价为 8.29 美元，市值为 17.4 亿美元。该公司报告了同比 49.5% 的收入增长，季度每股收益为 0.15 美元，超出预期。分析师对该股票给予 “适度买入” 的评级，目标价格范围为 8.00 美元至 18.00 美元</p>

<p>Boothbay Fund Management LLC decreased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 4.4% during the 1st quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 1,324,221 shares of the biotechnology company's stock after selling 60,412 shares during the period. Boothbay Fund Management LLC owned about 0.63% of BioCryst Pharmaceuticals worth $9,932,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Boothbay Fund Management LLC 在最近向证券交易委员会的披露中表示，在第一季度减少了对 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - 免费报告) 的持股比例，降幅为 4.4%。该公司在此期间出售了 60,412 股后，持有生物技术公司 1,324,221 股股票。Boothbay Fund Management LLC 在最近一个季度末持有的 BioCryst Pharmaceuticals 的股份约占 0.63%，价值 9,932,000 美元。</p>
</div><p>Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Allianz Asset Management GmbH raised its stake in BioCryst Pharmaceuticals by 9.6% in the 1st quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company's stock valued at $103,000 after acquiring an additional 1,200 shares during the period. Royal Bank of Canada boosted its holdings in shares of BioCryst Pharmaceuticals by 2.4% during the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company's stock worth $476,000 after buying an additional 1,458 shares during the period. SG Americas Securities LLC grew its stake in BioCryst Pharmaceuticals by 5.2% in the 1st quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company's stock valued at $326,000 after buying an additional 2,146 shares during the last quarter. Wellington Management Group LLP raised its holdings in BioCryst Pharmaceuticals by 2.6% in the 1st quarter. Wellington Management Group LLP now owns 91,348 shares of the biotechnology company's stock valued at $685,000 after acquiring an additional 2,291 shares during the period. Finally, Mariner LLC lifted its position in BioCryst Pharmaceuticals by 32.1% during the fourth quarter. Mariner LLC now owns 13,258 shares of the biotechnology company's stock worth $100,000 after acquiring an additional 3,224 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也对该公司的持仓进行了调整。安联资产管理有限公司在第一季度将其在 BioCryst Pharmaceuticals 的股份增加了 9.6%。安联资产管理有限公司目前持有 13,700 股生物技术公司的股票，价值 103,000 美元，此前在此期间又增持了 1,200 股。加拿大皇家银行在第一季度将其在 BioCryst Pharmaceuticals 的持股增加了 2.4%。加拿大皇家银行目前持有 63,463 股生物技术公司的股票，价值 476,000 美元，此前在此期间又增持了 1,458 股。SG Americas Securities LLC 在第一季度将其在 BioCryst Pharmaceuticals 的股份增加了 5.2%。SG Americas Securities LLC 目前持有 43,496 股生物技术公司的股票，价值 326,000 美元，此前在上个季度又增持了 2,146 股。威灵顿管理集团在第一季度将其在 BioCryst Pharmaceuticals 的持股增加了 2.6%。威灵顿管理集团目前持有 91,348 股生物技术公司的股票，价值 685,000 美元，此前在此期间又增持了 2,291 股。最后，Mariner LLC 在第四季度将其在 BioCryst Pharmaceuticals 的持仓增加了 32.1%。Mariner LLC 目前持有 13,258 股生物技术公司的股票，价值 100,000 美元，此前在上个季度又增持了 3,224 股。目前，85.88% 的股票由机构投资者持有。</p>
</div><h2>BioCryst Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>BioCryst Pharmaceuticals 价格表现</h2>
</div><p>NASDAQ:BCRX opened at $8.29 on Thursday. The firm has a market capitalization of $1.74 billion, a PE ratio of -46.05, a price-to-earnings-growth ratio of 1.89 and a beta of 1.13. The stock's 50-day simple moving average is $8.57 and its 200 day simple moving average is $8.77. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.01 and a twelve month high of $11.31.</p>
<div class="lb-trans"><p>NASDAQ:BCRX 周四开盘价为 8.29 美元。该公司的市值为 17.4 亿美元，市盈率为 -46.05，市盈率增长比率为 1.89，贝塔值为 1.13。该股票的 50 日简单移动平均线为 8.57 美元，200 日简单移动平均线为 8.77 美元。BioCryst Pharmaceuticals, Inc. 的 12 个月最低价为 6.01 美元，最高价为 11.31 美元。</p>
</div><p>BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.03 by $0.12. The company had revenue of $163.35 million during the quarter, compared to the consensus estimate of $149.59 million. BioCryst Pharmaceuticals's revenue for the quarter was up 49.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.06) EPS. On average, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>BioCryst Pharmaceuticals (NASDAQ:BCRX - 获取免费报告) 最近于 8 月 4 日星期一发布了季度财报。该生物技术公司报告本季度每股收益为 0.15 美元，超出市场共识预期的 0.03 美元，超出幅度为 0.12 美元。该公司在本季度的收入为 1.6335 亿美元，而市场共识预期为 1.4959 亿美元。BioCryst Pharmaceuticals 本季度的收入同比增长 49.5%。在去年同期，该公司每股收益为 -0.06 美元。分析师平均预计 BioCryst Pharmaceuticals, Inc. 本财年将发布 -0.36 美元的每股收益。</p>
</div><h2>Insider Transactions at BioCryst Pharmaceuticals</h2>
<div class="lb-trans"><h2>BioCryst Pharmaceuticals 内部交易</h2>
</div><p>In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the transaction, the director directly owned 65,352 shares in the company, valued at approximately $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. 5.10% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他 BioCryst Pharmaceuticals 的新闻中，董事 Theresa Heggie 于 8 月 13 日星期三出售了 70,000 股该股票。该股票的平均售价为 8.51 美元，总价值为 595,700.00 美元。交易完成后，该董事直接持有公司 65,352 股股票，估值约为 556,145.52 美元。这笔交易代表了他们持有股票的比例减少了 51.72%。该交易已在向证券交易委员会提交的文件中披露，可以通过此链接访问。目前，5.10% 的股票由内部人士持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>BCRX has been the subject of several research reports. Barclays lifted their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an &#34;equal weight&#34; rating in a report on Wednesday, May 7th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, July 26th. Royal Bank Of Canada reissued an &#34;outperform&#34; rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Bank of America raised their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, July 1st. Finally, Wedbush lifted their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, June 30th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $16.70.</p>
<div class="lb-trans"><p>BCRX 是多份研究报告的主题。巴克莱在 5 月 7 日的报告中将 BioCryst Pharmaceuticals 的目标价从 8.00 美元上调至 11.00 美元，并给予该股票 “持平” 评级。Wall Street Zen 在 7 月 26 日的研究报告中将 BioCryst Pharmaceuticals 的评级从 “买入” 上调至 “强力买入”。加拿大皇家银行在 6 月 30 日的报告中重申了 “跑赢大盘” 评级，并对 BioCryst Pharmaceuticals 的股票设定了 13.00 美元的目标价。美国银行在 7 月 1 日的报告中将 BioCryst Pharmaceuticals 的目标价从 13.00 美元上调至 15.00 美元，并给予该股票 “买入” 评级。最后，Wedbush 在 6 月 30 日的研究报告中将 BioCryst Pharmaceuticals 的目标价从 16.00 美元上调至 18.00 美元，并给予该公司 “跑赢大盘” 评级。九位投资分析师对该股票给予了 “买入” 评级，一位分析师给予了 “持有” 评级。根据 MarketBeat.com 的数据，BioCryst Pharmaceuticals 目前的平均评级为 “适度买入”，共识目标价为 16.70 美元。</p>
</div><p><strong>Read Our Latest Analysis on BioCryst Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 BioCryst Pharmaceuticals 的最新分析</strong></p>
</div><h2>About BioCryst Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 BioCryst Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.</p>
<div class="lb-trans"><p>BioCryst Pharmaceuticals, Inc. 是一家生物技术公司，开发口服小分子和蛋白质治疗药物以治疗罕见疾病。该公司销售的药物包括用于治疗急性非复杂流感的静脉注射药物 peramivir，商品名为 RAPIVAB、RAPIACTA 和 PERAMIFLU；以及用于治疗遗传性血管性水肿的口服丝氨酸蛋白酶抑制剂 ORLADEYO。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than BioCryst Pharmaceuticals</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>Return of the ETFs: 3 Names That Could Keep Outperforming</li>
<li>Stock Splits, Do They Really Impact Investors?</li>
<li>Back-to-School Shopping Hits $40B: 3 Retail Stocks to Watch Now</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>Alphabet Stock Surges After Dodging Harsh Antitrust Remedies</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 BioCryst Pharmaceuticals</li>
<li>技术股解析：关于科技你需要知道的事</li>
<li>ETF 的回归：三只可能持续表现优异的股票</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>开学购物达到 400 亿美元：现在值得关注的三只零售股票</li>
<li>现在值得购买的三只沃伦·巴菲特股票</li>
<li>Alphabet 股票在躲避严厉的反垄断措施后大幅上涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNSWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=BCRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in BioCryst Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 BioCryst 制药吗？</h2>
</div><p>Before you consider BioCryst Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 BioCryst 制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 BioCryst 制药并不在名单上。</p>
</div><p>While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 BioCryst 制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Boothbay Fund Management LLC 出售了 60,412 股 BioCryst 制药公司（股票代码：BCRX）的股票